All In Biotech

Drug Trial Radar · NCT06809803

Extended-release Sodium Oxybate in Children

Safety, Convenience, and Tolerability of a Nightly Single Oral Dose of Extended-release Sodium Oxybate in Children

Last checked: Nov 20, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Oct 27, 2025

Primary completion

Jun 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Stanford UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Avadel
First posted
Feb 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 7 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objectives of this study are to determine the treatment preferences of children with narcolepsy type 1 between Extended-release sodium oxybate and Non-extended-release oxybates (Sodium oxybate or a medication with the combination of Calcium, magnesium, potassium, and sodium oxybates). The study will also assess the safety, convenience, and tolerability of Extended-release sodium oxybate. Additionally, the researchers aim to assess how well Extended-release sodium oxybate works in treating narcolepsy type 1.

Conditions

  • Narcolepsy Type 1 (NT 1)

Interventions

  • Extended-release sodium oxybateDrug

    Participants will take Extended-release sodium Oxybate (Lumryz) 4.5-9 g oral suspension in approximately ⅓ cup of water orally once a day before bedtime. Dosage of Lumryz will be the same as the equivalent total dose of the Non-Extended-release Oxybate (Xywav or Xyrem) that participants use before starting the study

  • Non-extended-release oxybatesDrug

    Participants will take Non-Extended-release Oxybates (Xyrem oral solution or Xywav oral solution) 4.5-9 g orally per night (divided into two doses, once before bedtime and another dose 2-4 hours later) at the same dose of Xyrem or Xywav that participants use before starting the study will be continued to compare with Extended-release sodium Oxybate (Lumryz)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participant preference for selecting the extended vs non-extended release oxybatesTime frame: Baseline, up to 8-12 weeks through study completion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Redwood City, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.